Navigation Links
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Date:3/13/2009

te GI GVHD and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the first half of 2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, Inc., please visit the Company's website at www.dorbiopharma.com.

This press release contains forward-looking statements that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec(R), particularly in light of the significant uncertainty inherent in developing vaccines against bioter
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
2. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
4. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
5. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
6. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
7. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
8. Eiger BioPharmaceuticals Raises $7.1 Million A Round
9. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
10. Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm
11. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 18, 2014 Reports from ... the United States suffer from one or more chronic ... or cancer. Medication can address some of these diseases, ... activities that many sufferers face. While implanted nerve stimulation ... stimulate the whole nerve, which can induce side effects. ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
(Date:12/17/2014)... Achim Noack has been named global ... In this position, Noack will assist Jerry Stoller, CEO ... marketing strategy and supervise global marketing management and implementation ... tremendous knowledge and experience in the crop protection industry,” ... and innovative thinking will be a great asset for ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... ... ... ... ...
... failure affects the surface of an individual heart muscle ... technique developed at Imperial College London. The findings may ... can slow the development of heart failure, and to ... and abnormal heart rhythms. Heart failure is ...
... ... molding, two-material molding and micro-molding for medical device components and assemblies, has promoted Greg ... ... single-source provider of silicone molding, two-material molding and micro-molding for medical device components and ...
Cached Biology Technology:Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 3Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 4Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 5Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 6Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 7Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 8Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 9Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 10Researchers gain detailed insight into failing heart cells using new nano technique 2Researchers gain detailed insight into failing heart cells using new nano technique 3Riemer Named President of Medical Device Manufacturer MRPC 2
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season ... industry as Acuity Market Intelligence reports that the ... be open. Acuity forecasts that intensifying demand for ... incorporate biometrics will drive a global market of ... devices by 2020.   According to ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... of the "iPhone 5S Fingerprint Sensor - ... report to their offering. ... of AuthenTec in July 2012, Apple introduced the ... is currently the only device of Apple incorporating ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... the "Micro Market Monitor: North America Perimeter Security ... http://photos.prnewswire.com/prnh/20130307/600769 The North ... a CAGR of 3.6% from 2014 to 2019. Although ... market, Canada is expected to ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... pollen next, you have to literally think like one. , ... are more likely to stick with it rather than invest ... student at the University of Wisconsin-Milwaukee (UWM). , Flanigan ... bees as they gather pollen ?which plant species the bees ...
... five-year, $1 million grant from the National Cancer Institute, a ... improve the effectiveness of a drug that he developed ... Waldemar Debinski, M.D., Ph.D., pioneered a method to destroy cells ... The drug is currently being tested in clinical trials and ...
... research team led by scientists at the Broad Institute of ... kind of genetic "roadmap" that can connect human diseases with ... new drugs work in human cells. Called the "Connectivity Map," ... September 29 issue of Science and in separate publications in ...
Cached Biology News:Researchers find that bumblebees' flower choice matters 2Researchers find that bumblebees' flower choice matters 3Researchers find that bumblebees' flower choice matters 4Scientist works to improve treatment for brain tumors 2Genetic 'roadmap' charts links between drugs and human disease 2Genetic 'roadmap' charts links between drugs and human disease 3
... from frozen embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 7microns and ... (3-5mm in diameter) in comparison to core ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5mm in diameter) ...
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... DNA Engine Opticon real-time PCR detection system ... fluorescence excitation (450-495 nm) and a photomultiplier ... Opticon system is built on an DNA ... thermal gradient feature. This item includes the ...
Biology Products: